LIMNW
Liminatus Pharma, Inc.
Price Chart
Latest Quote
$0.07
+0.00 (+0.00%)
Current Price
| Previous Close | $0.07 |
| Open | $0.07 |
| Day High | $0.07 |
| Day Low | $0.07 |
| Volume | 2,500 |
Stock Information
| Total Debt | $1.44M |
| Cash Equivalents | $1.91M |
| Net Income | $-11.00M |
| Exchange | NCM |
đ Comprehensive Analysis
Company Data
| Income | $-11.00M |
| Book/sh | $-0.00 |
| Employees | 1 |
Financial Ratios
| Quick Ratio | 0.66 |
| Current Ratio | 0.96 |
Returns & Margins
Ownership
| Insider & Institutional transactions data not available |
Valuation Ratios
| P/B | -22.87 |
Analyst Data
| Recommendation | none |
Technical Indicators
| SMA20 | $0.06 |
| SMA50 | $0.06 |
| RSI | nan |
| Shares Float | 29.07M |
| Volatility | 0.70 |
Performance History
| Week | +0.00% |
| Month | +0.00% |
| Quarter | +0.00% |
| YTD | -24.05% |
| 10 Years | -24.05% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-18 | $0.06 | 0 |
| 2026-06-17 | $0.06 | 0 |
| 2026-06-16 | $0.06 | 0 |
| 2026-06-15 | $0.06 | 0 |
| 2026-06-12 | $0.06 | 0 |
| 2026-06-11 | $0.06 | 0 |
| 2026-06-10 | $0.06 | 0 |
| 2026-06-09 | $0.06 | 0 |
| 2026-06-08 | $0.06 | 0 |
| 2026-06-05 | $0.06 | 0 |
| 2026-06-04 | $0.06 | 0 |
| 2026-06-03 | $0.06 | 0 |
| 2026-06-02 | $0.06 | 0 |
| 2026-06-01 | $0.06 | 0 |
| 2026-05-29 | $0.06 | 0 |
| 2026-05-28 | $0.06 | 0 |
| 2026-05-27 | $0.06 | 0 |
| 2026-05-26 | $0.06 | 0 |
About Liminatus Pharma, Inc.
Liminatus Pharma, Inc., a pre-clinical stage biopharmaceutical company, engages in the development of cancer therapies in the United States. It develops IBA101, a humanized anti CD47 monoclonal antibody, which is in Phase I clinical trial for the treatment of advanced solid cancers, including non-small cell lung cancer. The company was founded in 2018 and is based in Cerritos, California.
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Total Revenue | $0 | $0 | $0 | $0 |
| Operating Revenue | $0 | $0 | $0 | $0 |
| Expenses | ||||
| Interest Expense | $215,903 | $338,882 | $175,000 | $219,000 |
| Total Expenses | $2,967,812 | $3,329,953 | $4,819,000 | $2,709,000 |
| Other Income Expense | $-7,099,391 | - | - | - |
| Other Non Operating Income Expenses | $-7,556,000 | - | - | - |
| Net Non Operating Interest Income Expense | $-139,314 | $-216,356 | $-165,000 | $-219,000 |
| Interest Expense Non Operating | $215,903 | $338,882 | $175,000 | $219,000 |
| Operating Expense | $2,967,812 | $3,329,953 | $4,819,000 | $2,709,000 |
| General And Administrative Expense | $2,967,812 | $644,619 | $1,062,000 | $856,000 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-10,206,517 | $-3,546,309 | $-4,984,000 | $-2,928,000 |
| Net Interest Income | $-139,314 | $-216,356 | $-165,000 | $-219,000 |
| Interest Income | $76,589 | $122,526 | $10,000 | $0 |
| Normalized Income | $-10,663,126 | $-3,546,309 | $-4,984,000 | $-2,928,000 |
| Net Income From Continuing And Discontinued Operation | $-10,206,517 | $-3,546,309 | $-4,984,000 | $-2,928,000 |
| Total Operating Income As Reported | $-2,967,812 | $-3,329,953 | $-4,819,000 | $-2,709,000 |
| Net Income Common Stockholders | $-10,206,517 | $-3,546,309 | $-4,984,000 | $-2,928,000 |
| Net Income | $-10,206,517 | $-3,546,309 | $-4,984,000 | $-2,928,000 |
| Net Income Including Noncontrolling Interests | $-10,206,517 | $-3,546,309 | $-4,984,000 | $-2,928,000 |
| Net Income Continuous Operations | $-10,206,517 | $-3,546,309 | $-4,984,000 | $-2,928,000 |
| Pretax Income | $-10,206,517 | $-3,546,309 | $-4,984,000 | $-2,928,000 |
| Special Income Charges | $402,297 | $0 | - | - |
| Interest Income Non Operating | $76,589 | $122,526 | $10,000 | $0 |
| Operating Income | $-2,967,812 | $-3,329,953 | $-4,819,000 | $-2,709,000 |
| Other | ||||
| Tax Effect Of Unusual Items | $0 | $0 | $0 | $0 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-10,445,395 | $-3,207,427 | $-4,809,000 | $-2,709,000 |
| Total Unusual Items | $456,609 | $0 | - | - |
| Total Unusual Items Excluding Goodwill | $456,609 | $0 | - | - |
| Reconciled Depreciation | $1,828 | $0 | - | - |
| EBITDA (Bullshit earnings) | $-9,988,786 | $-3,207,427 | $-4,809,000 | $-2,709,000 |
| EBIT | $-9,990,614 | $-3,207,427 | $-4,809,000 | $-2,709,000 |
| Diluted NI Availto Com Stockholders | $-10,206,517 | $-3,546,309 | $-4,984,000 | $-2,928,000 |
| Other Special Charges | $-402,297 | - | - | - |
| Gain On Sale Of Security | $54,312 | - | - | - |
| Research And Development | $0 | $2,685,334 | $3,757,000 | $1,853,000 |
| Selling General And Administration | $2,967,812 | $644,619 | $1,062,000 | $856,000 |
| Other Gand A | $2,967,812 | $644,619 | $1,062,000 | $856,000 |
Fetched: 2026-06-22
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $-9,814,690 | $-19,340,063 | $0 | $0 |
| Total Assets | $512,795 | $5,408,859 | $2,242,000 | $6,843,000 |
| Total Non Current Assets | $12,221 | $127,216 | $1,000 | $1,000 |
| Current Assets | $500,574 | $5,281,643 | $2,241,000 | $6,842,000 |
| Other Current Assets | $162,919 | $155,501 | $22,000 | $10,000 |
| Current Deferred Assets | $0 | $1,401,323 | $840,000 | $0 |
| Receivables | $0 | $3,668,500 | $945,000 | $100,000 |
| Loans Receivable | $0 | $3,668,500 | $819,000 | $0 |
| Cash Cash Equivalents And Short Term Investments | $337,655 | $56,319 | $434,000 | $5,048,000 |
| Cash And Cash Equivalents | $337,655 | $56,319 | $434,000 | $5,048,000 |
| Cash Financial | $337,655 | $56,319 | $434,000 | $5,048,000 |
| Non Current Accounts Receivable | - | $126,275 | - | - |
| Prepaid Assets | - | - | $0 | $1,684,000 |
| Debt | ||||
| Net Debt | $1,104,845 | $19,916,681 | $15,616,000 | $11,452,000 |
| Total Debt | $1,442,500 | $19,973,000 | $16,050,000 | $16,500,000 |
| Current Debt And Capital Lease Obligation | $1,442,500 | $19,973,000 | $16,050,000 | $16,500,000 |
| Current Debt | $1,442,500 | $19,973,000 | $16,050,000 | $16,500,000 |
| Other Current Borrowings | $1,442,500 | $19,973,000 | $16,050,000 | $16,500,000 |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $10,327,485 | $24,748,922 | $18,036,000 | $17,653,000 |
| Total Non Current Liabilities Net Minority Interest | $29,244 | $0 | $0 | $0 |
| Derivative Product Liabilities | $29,244 | $0 | - | - |
| Current Liabilities | $10,298,241 | $24,748,922 | $18,036,000 | $17,653,000 |
| Current Deferred Liabilities | $500,000 | $0 | - | - |
| Payables And Accrued Expenses | $8,855,741 | $4,775,922 | $1,986,000 | $1,153,000 |
| Interest Payable | $203,921 | $955,119 | $616,000 | $441,000 |
| Payables | $8,651,820 | $3,460,803 | $1,370,000 | $712,000 |
| Other Payable | $7,860,000 | - | $242,000 | - |
| Accounts Payable | $582,234 | $1,483,253 | $933,000 | $508,000 |
| Equity | ||||
| Common Stock Equity | $-9,814,690 | $-19,340,063 | $-15,794,000 | $-10,810,000 |
| Total Equity Gross Minority Interest | $-9,814,690 | $-19,340,063 | $-15,794,000 | $-10,810,000 |
| Stockholders Equity | $-9,814,690 | $-19,340,063 | $0 | $0 |
| Retained Earnings | $-38,871,733 | $-28,665,216 | $-25,119,000 | $-20,135,000 |
| Other | ||||
| Ordinary Shares Number | $27,064,633 | $26,014,633 | $26,014,633 | $26,014,633 |
| Share Issued | $27,064,633 | $26,014,633 | $26,014,633 | $26,014,633 |
| Tangible Book Value | $-9,814,690 | $-19,340,063 | $-15,794,000 | $-10,810,000 |
| Invested Capital | $-8,372,190 | $632,937 | $256,000 | $5,690,000 |
| Working Capital | $-9,797,667 | $-19,467,279 | $-15,795,000 | $-10,811,000 |
| Total Capitalization | $-9,814,690 | $-19,340,063 | $-15,794,000 | $-10,810,000 |
| Additional Paid In Capital | $29,054,337 | $9,323,403 | - | - |
| Capital Stock | $2,706 | $1,750 | - | - |
| Common Stock | $2,706 | $1,750 | - | - |
| Preferred Stock | $0 | $0 | - | - |
| Current Accrued Expenses | $203,921 | $1,315,119 | $616,000 | $441,000 |
| Dueto Related Parties Current | $209,586 | $1,977,550 | $437,000 | $204,000 |
| Duefrom Related Parties Non Current | $0 | $126,275 | - | - |
| Net PPE | $12,221 | $941 | $1,000 | $1,000 |
| Total Partnership Capital | - | - | $-15,794,000 | $-10,810,000 |
| General Partnership Capital | - | - | $4,611,000 | $5,158,000 |
| Limited Partnership Capital | - | - | $4,714,000 | $4,167,000 |
| Duefrom Related Parties Current | - | - | $126,000 | $100,000 |
Fetched: 2026-06-22
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-9,976,426 | $-1,451,066 | $-3,345,000 | $-869,000 |
| Operating Activities | ||||
| Operating Cash Flow | $-9,963,318 | $-1,451,066 | $-3,345,000 | $-869,000 |
| Cash Flow From Continuing Operating Activities | $-9,963,318 | $-1,451,066 | $-3,345,000 | $-869,000 |
| Operating Gains Losses | $7,305,688 | - | - | - |
| Investing Activities | ||||
| Capital Expenditure | $-13,108 | - | - | - |
| Investing Cash Flow | $-788,108 | $-2,850,000 | $-819,000 | $0 |
| Cash Flow From Continuing Investing Activities | $-788,108 | $-2,850,000 | $-819,000 | $0 |
| Net Other Investing Changes | $-775,000 | $-2,850,000 | $-819,000 | - |
| Financing Activities | ||||
| Issuance Of Capital Stock | $10,556,500 | $0 | $0 | $4,200,000 |
| Financing Cash Flow | $11,032,762 | $3,923,000 | $-450,000 | $5,917,000 |
| Cash Flow From Continuing Financing Activities | $11,032,762 | $3,923,000 | $-450,000 | $5,917,000 |
| Net Other Financing Charges | $-2,563,738 | - | - | - |
| Net Common Stock Issuance | $10,556,500 | $0 | $0 | $3,500,000 |
| Common Stock Issuance | $10,556,500 | $0 | $0 | $4,200,000 |
| Repurchase Of Capital Stock | - | - | $0 | $-700,000 |
| Other | ||||
| Repayment Of Debt | $-1,300,000 | $0 | $-3,856,000 | $-7,025,000 |
| Issuance Of Debt | $4,340,000 | $3,923,000 | $3,406,000 | $9,442,000 |
| End Cash Position | $337,655 | $56,319 | $434,000 | $5,048,000 |
| Beginning Cash Position | $56,319 | $434,385 | $5,048,000 | $0 |
| Changes In Cash | $281,336 | $-378,066 | $-4,614,000 | $5,048,000 |
| Net Issuance Payments Of Debt | $3,040,000 | $3,923,000 | $-450,000 | $2,417,000 |
| Net Short Term Debt Issuance | $3,040,000 | $3,923,000 | $-450,000 | $2,417,000 |
| Short Term Debt Payments | $-1,300,000 | $0 | $-3,856,000 | $-7,025,000 |
| Short Term Debt Issuance | $4,340,000 | $3,923,000 | $3,406,000 | $9,442,000 |
| Net PPE Purchase And Sale | $-13,108 | $0 | - | - |
| Purchase Of PPE | $-13,108 | $0 | - | - |
| Change In Working Capital | $-6,984,295 | $2,095,243 | $1,639,000 | $1,159,000 |
| Change In Other Current Assets | $324,609 | $-133,251 | $-12,000 | $-10,000 |
| Change In Payables And Accrued Expense | $-3,881,904 | $2,228,494 | $807,000 | $216,000 |
| Change In Accrued Expense | $215,903 | $698,882 | $175,000 | $109,000 |
| Change In Interest Payable | $215,903 | $338,882 | $175,000 | $109,000 |
| Change In Payable | $-4,097,807 | $1,529,612 | $632,000 | $107,000 |
| Change In Account Payable | $-4,035,340 | $-10,747 | $425,000 | $89,000 |
| Change In Receivables | $-3,427,000 | $0 | - | - |
| Other Non Cash Items | $-80,022 | - | - | $900,000 |
| Depreciation Amortization Depletion | $1,828 | $0 | - | - |
| Depreciation And Amortization | $1,828 | $0 | - | - |
| Depreciation | $1,828 | $0 | - | - |
| Gain Loss On Investment Securities | $-54,312 | - | - | - |
| Gain Loss On Sale Of PPE | $7,360,000 | $0 | - | - |
| Net Income From Continuing Operations | $-10,206,517 | $-3,546,309 | $-4,984,000 | $-2,928,000 |
| Interest Paid Supplemental Data | - | - | $0 | $503,000 |
| Income Tax Paid Supplemental Data | - | - | $0 | $0 |
| Common Stock Payments | - | - | $0 | $-700,000 |
| Change In Other Working Capital | - | - | $-840,000 | - |
| Change In Prepaid Assets | - | - | $1,684,000 | $953,000 |
Fetched: 2026-06-22